A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer

Jung Ki Jo, Jong Jin Oh, Young Tae Kim, Hong Sang Moon, Hong Yong Choi, Seunghyun Park, Jin‐Nyoung Ho, Sungroh Yoon, Hae Young Park, Seok‐Soo ByunOncotarget 2017 · DOI

TL;DR

This study identifies a specific genetic variant (rs56350726 in the SLC28A3 gene) that is associated with both the development of metastatic prostate cancer (mPCa) and its progression to castration-resistant prostate cancer (CRPC) in a Korean population. This finding offers a potential new biomarker for predicting which patients are at higher risk of developing more aggressive forms of the disease, paving the way for more personalized treatment strategies.

What Problem Does This Paper Address?

Prostate cancer (PCa) is a leading cause of cancer-related death globally. While androgen-deprivation therapy (ADT) is a standard treatment for advanced PCa, many patients eventually develop castration-resistant prostate cancer (CRPC), a more aggressive and difficult-to-treat form. Understanding the factors that contribute to the development of metastatic PCa (mPCa) and its progression to CRPC is crucial for improving patient outcomes. However, the genetic underpinnings of these processes, particularly in relation to treatment response, remain largely unclear. This paper aims to fill this knowledge gap by investigating the association between genetic variations and the progression of PCa to metastatic and castration-resistant stages.

Methods

The researchers employed a comprehensive genetic analysis approach. They utilized the HumanExome BeadChip v1.0 platform to genotype 242,221 single nucleotide polymorphisms (SNPs) in a cohort of 1000 Korean men diagnosed with prostate cancer.

Key methodological steps included:

  • Association analysis with metastasis: Logistic regression was used to identify SNPs significantly associated with the presence of metastasis at diagnosis.
  • Time-to-event analysis for CRPC progression: For a subset of 110 patients treated with ADT, Kaplan-Meier analysis and Cox proportional hazards models were used to assess the association between identified SNPs and the time to progression to CRPC.
  • Multivariable analysis: To account for other clinical factors, multivariable Cox regression was performed, including age, PSA levels, and Gleason score alongside the genetic variants.

Datasets

The study used a dataset of 1000 Korean male patients diagnosed with prostate cancer. This cohort was stratified into two groups: those with and without metastasis at diagnosis. A subset of 110 patients from this cohort who were treated with hormone therapy (ADT) were specifically analyzed for progression to CRPC.

Key Insights and Ideas

  • Genetic predisposition to metastasis: The study identified five SNPs that were significantly associated with metastatic prostate cancer. This suggests that an individual's genetic makeup can play a role in the likelihood of PCa spreading.
  • A specific SNP predicts CRPC progression: The most significant finding is the identification of the SNP rs56350726 within the SLC28A3 gene as being strongly associated with the time to progression to CRPC in patients undergoing ADT. This is a critical insight as it points to a potential predictive biomarker for treatment resistance.
  • SLC28A3's potential role: The SLC28A3 gene encodes a nucleoside transporter. The researchers hypothesize that variants in this gene might influence the transport of ADT or play a role in androgen synthetic pathways, thereby affecting treatment response.
  • Biomarker potential: The identified genetic variant offers the possibility of developing a novel, clinically adaptable biomarker for predicting which patients are at higher risk of developing CRPC. This could enable more personalized treatment approaches.

Key Results

  • Five top SNPs associated with mPCa: The analysis revealed five SNPs that were significantly associated with metastatic PCa.
  • rs56350726 and CRPC progression: In Kaplan-Meier analysis, patients carrying the rs56350726 variant showed a significantly shorter time to CRPC (5-year CRPC-free survival rate of 32.3% vs. 79.9% for non-carriers, p = 0.019).
  • Independent predictor of CRPC: In multivariable Cox regression, rs56350726 was found to be an independent predictor of CRPC progression, with a hazard ratio (HR) of 4.172 (95% CI = 1.223–14.239, p = 0.023).

Limitations and Future Work

The authors acknowledge several limitations:

  • Discrepancy in group sizes: The number of patients in the metastatic group (41) was significantly smaller than in the non-metastatic group (959).
  • Homogenous racial population: The study was conducted on a Korean population, and the findings may not be directly generalizable to other ethnic groups due to potential genetic and environmental differences.
  • Treatment variations: The study cohort included patients treated with different ADT regimens (intermittent vs. continuous), which could influence progression rates. The number of patients treated with orchiectomy was also small, limiting analysis of this treatment type.
  • Limited scope of genetic analysis: The study focused on exome sequencing and did not perform whole-genome analysis.

Future work should focus on:

  • Large-scale, multi-ethnic validation: A larger, more diverse study is needed to validate these findings across different populations.
  • Functional studies: Further research is required to elucidate the precise biological mechanisms by which the rs56350726 variant in SLC28A3 influences ADT response and CRPC progression.
  • Development of clinical tools: The potential of rs56350726 as a predictive biomarker for CRPC progression should be explored for clinical application.

Summary updated

Abstract

Based on a genetic variation, the five top SNPs were observed to associate with mPCa. And one (SLC28A3, rs56350726) of five SNP was found the association with the progression to CRPC in patients with mPCa.
BibTeX
@inproceedings{jo2017genetic,
  author = {Jung Ki Jo and Jong Jin Oh and Young Tae Kim and Hong Sang Moon and Hong Yong Choi and Seunghyun Park and Jin‐Nyoung Ho and Sungroh Yoon and Hae Young Park and Seok‐Soo Byun},
  title = {{A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer}},
  booktitle = {Oncotarget},
  year = {2017},
  doi = {10.18632/oncotarget.18298},
}
Figure